Drug Profile
ONO 4578
Alternative Names: BMS 986310; ONO-4578Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Ono Pharmaceutical
- Developer Bristol-Myers Squibb; Ono Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer
- Phase I/II Solid tumours
- Phase I Colorectal cancer; HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 18 Jan 2024 Efficacy and adverse event data from a phase I trial in Solid tumours presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 06 Dec 2023 Phase-II clinical trials in Gastric cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Recurrent) in Japan (PO) (NCT06256328)
- 20 Oct 2023 ONO 4578 is still in phase I trials for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Japan (PO) (NCT03155061)